This content is in French.
Cetuximab: game changer or a mere drop in the ocean?
19 mars 2025
#ColorectalCancer #Chemotherapy #Cetuximab #AntiEGFR #Survival #TargetedTherapy
Metastatic colorectal cancer (mCRC) is an advanced and aggressive form of colorectal cancer characterized by the spread of tumor cells to other organs, particularly the liver and lungs. Its prognosis is poor, with a 5-year survival rate estimated at only 14%, compared to 90% for localized forms. This significant difference is due to the complexity of treating metastases and the development of resistance to standard therapies.
Metastatic colorectal cancer (mCRC) is an advanced and aggressive form of colorectal cancer characterized by the spread of tumor cells to other organs, particularly the liver and lungs. Its prognosis is poor, with a 5-year survival rate estimated at only 14%, compared to 90% for localized forms. This significant difference is due to the complexity of treating metastases and the development of resistance to standard therapies.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Azeem, M., et al. (2025). The impact of combining cetuximab with the traditional chemotherapy regimens on clinical effectiveness in metastatic colorectal cancer: a systematic review and meta-analysis. BMC cancer, 25(1), 33
View the source
